Humacyte vs Pluri
HUMA and PLUR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HUMA and PLUR compare
Humacyte is the larger company, worth 11 times as much as Pluri ($164M against $14.8M).
Humacyte grew revenue faster over the last twelve months (52.5% versus −24.0% for Pluri).
Pluri keeps more of each dollar of sales as profit, with a net margin of −2345% compared with −3955% at Humacyte.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HUMA | PLUR |
|---|---|---|
| Size and price | ||
| Market cap | $164M | $14.8M |
| Share price | $0.592 | $1.20 |
| Change, 1 year | −56.2% | −69.2% |
| Change, 5 years | −94.6% | −94.3% |
| Beta (5Y) | 2.06 | 0.97 |
| Employees | 184 | 92 |
| StockData Score | ||
| Total score | 2 | 2 |
| Valuation score | 0 | 0 |
| Growth score | 1 | 1 |
| Performance score | 0 | 1 (better) |
| Health score | 1 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 68.6× | 14.6× (better) |
| P/B | 9.1× | – |
| FCF yield | −53.9% (better) | −137% |
| Growth | ||
| Revenue growth (TTM) | 52.5% (better) | −24.0% |
| Profitability | ||
| Gross margin | −475% | 44.6% (better) |
| Operating margin | −4603% | −2455% (better) |
| Net margin | −3955% | −2345% (better) |
| FCF margin | −3697% | −1990% (better) |
| Return on equity | −1424% | – |
| Financial health | ||
| Interest coverage | −11.0× (better) | −26.8× |
| Current ratio | 3.34 (better) | 0.27 |
| Altman Z-score | −10.29 (better) | −30.49 |
| Piotroski F-score | 4 (better) | 1 |
| Dividends and buybacks | ||
| Buyback yield | – | −34.3% |
| Shareholder yield | 0.00% (better) | −34.3% |
| Ownership | ||
| Held by institutions | 26.4% | 0.22% |
| Held by insiders | 8.0% | 54.6% |
| Insider net buying, 12 months | $7.4K | $1.3M (better) |
| Short interest, % of float | 11.0% | 1.4% |
Go deeper
- HUMA stock overview
- HUMA income statement
- HUMA valuation and score
- PLUR stock overview
- PLUR income statement
- PLUR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.